Dopamine in schizophrenia

Annals of Medicine

Volumn 28, Issue 6, 1996, Pages 557-561

  Hietala, Jarmo ^a   Syvälahti, Erkka ^b  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b UNIVERSITY OF TURKU   (Finland)

Author keywords

Brain; Dopamine; Neurotransmission; Schizophrenia

Indexed keywords

DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; NEUROTRANSMITTER;

BRAIN ASYMMETRY; DOPAMINE BRAIN LEVEL; HUMAN; NARCOLEPSY; NEUROTRANSMISSION; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOLID;

EID: 0030466269     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899608999120     Document Type: Review

References (43)

1. van Rossum JM. The significance of dopamine receptor blockade for the action of neuroleptic drugs. In: Brill H, Cole JO, Deniker P, Hippius H, Bradley PB, eds. Proceedings of the Fifth CINP. Amsterdam: Excerpta Medica, 1967: 321-9.
2. Carlsson A, Lindquist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963; 20: 140-4.
3. Bannon MJ, Roth RH. Pharmacology of mesocortical dopamine neurons. Pharmacol Rev 1983; 35: 63-8.
4. Andreasen N. Brain imaging: applications in psychiatry. Science 1988; 239: 1381-8.
5. Davis KL, Kahn RS, Ko G, Davidson M. Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 1991; 148: 1474-86.
6. Meltzer HY, Sommers AA, Luchins DJ. The effect of neuroleptics and other psychotropic drugs on negative symptoms in schizophrenia. J Clin Psychopharmacol 1986; 6: 329-38.
7. Crow TJ. Molecular pathology of schizophrenia: more than one disease process? BMJ 1980; 280: 66-8.
8. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.
9. Weinberger DR. Schizophrenia: from neuropathology to neurodevelopment. Lancet 1995; 346: 552-7.
10. Silbersweig DA, Stern E, Frith C, et al. A functional neuroanatomy of hallucinations in schizophrenia. Nature 1995; 378: 176-9.
11. Carlsson M, Carlsson A. Schizophrenia: a subcortical neurotransmitter imbalance syndrome? Schizophrenia Bull 1990; 16: 425-32.
12. Connell P. Amphetamine Psychosis. Maudsley Monograph, Vol. 5. London: Chapman & Hall, 1958.
13. van Rossum JM. The significance of dopamine receptor blockade for the mechanism of action of neuroleptic drugs. Arch Int Pharmacodyn Ther 1966; 160: 492-4.
14. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of neuroleptic drugs. Science 1976; 192: 481-3.
15. Seeman P, Lee T, Chau-Wong M, Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 1976; 261: 717-9.
16. 2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 1988; 45: 71-6.
17. Nordström AL, Farde L, Halldin C. Time course of D2 dopamine receptor occupancy examined by PET after single oral doses of haloperidol. Psychopharmacology 1992; 106: 433-8.
18. White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983; 221: 1054-7.
19. Chiodo LA, Bunney BS. Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983; 3: 1607-19.
20. Carpenter WT, Buchanan RW. Schizophrenia. N Engl J Med 1994; 330: 681-91.
21. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-96.
22. Benkert O, Muller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia - a review. Eur Neuropsychopharmacol 1995 (Suppl); 5: 43-53.
23. Seeman P, Guan H-C, van Tol H. Dopamine D4 receptors are elevated in schizophrenia. Nature 1993; 365: 441-5.
24. Reynolds GP, Mason S. Are striatal dopamine D4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576-7.
25. 3H-apomorphine in schizophrenic brains. Nature 1978; 274: 897-900.
26. 2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's and Huntington's diseases. Neuropsychopharmacology 1987; 1: 5-15.
27. Seeman P, Niznik HB. Dopamine receptors and transporters in Parkinson's disease and schizophrenia. FASEB J 1990; 4: 2737-44.
28. Burt DR, Creese I, Snyder SH. Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science 1977; 196: 326-8.
29. Kornhuber J, Riederer P, Reynolds GP, Beckmann H, Jellinger K, Gabriel E. 3H-spiperone binding in post-mortem brains of schizophrenic patients: relationship to neuroleptic drug treatment, abnormal movements and positive symptoms. J Neural Transm 1989; 75: 1-10.
30. 2 dopamine receptors in drug-naive schizophrenics. Science 1986; 234: 1558-63.
31. 2 dopamine receptor density estimates in schizophrenia: a positron emission tomography study with 11C-N-methylspiperone. Psychiatry Res 1993; 49: 219-7.
32. 11C] raclopride. Arch Gen Psychiatry 1990; 47: 213-9.
33. Nordström AL, Farde L, Eriksson L Halldin C. No elevated D2 dopamine receptors in neuroleptic naive schizophrenic patients revealed by positron emission tomography and [11C]-N-methylspiperone. Psychiatry Res 1995; 61: 67-83.
34. 2 receptor binding characteristics in neuroleptic-naive schizophrenics studied with positron emission tomography. Arch Gen Psychiatry 1994; 51: 116-23.
35. 2 dopaminergic receptors assessed with positron emission tomography and 76-Br-bromospiperone in untreated patients. Am J Psychiatry 1990; 147: 44-50.
36. 2 receptors in schizophrenia. A study with positron emission tomography and 76Br-bromolisuride. Br J Psychiatry 1991; 158: 346-50.
37. 2 dopamine receptor binding in the basal ganglia of antipsychotic-free schizophrenic patients. An 123-I-IBZM single photon emission computerised tomography study. Br J Psychiatry 1994; 164: 16-26.
38. Gejman PV, Ram A, Gelernter J, et al. No structural mutation in the D2 receptor gene in alcoholism and schizophrenia. Analysis using denaturing gradient gel electroforesis. JAMA 1994; 271: 204-8.
39. 11C]-FLB 457. Eur J Psychiatry 1994; 9 (Suppl 1), 55.
40. Sedvall G, Farde L. Chemical brain anatomy in schizophrenia. Lancet 1995; 346: 743-9.
41. Hietala J, Syvälahti E, Vuorio K, et al. Presynaptic dopamine function in striatum of neuroleptic-naive schizophrenic patients. Lancet 1995; 346: 1130-1.
42. Reith J, Benkelfat C, Sherwin A, et al. Elevated dopa decarboxylase activity in living brain of patients with psychosis. Proc Natl Acad Sci USA 1994; 91: 11651-4.
43. Pearlson GD, Wong DF, Tune LE, et al. In vivo D2 dopamine receptor density in psychotic and nonpsychotic patients with bipolar disorder. Arch Gen Psychiatry 1995; 52: 471-7.